MedCheck in English No.36
➡Download PDF Free ～Click here～
Editorial
Multitude of Medical Practices with Limited Efficacy
New Products
New Anti-Cholesterol Bempedoic Acid(Nexletol® )
A Dangerous Substance That May Shorten Life
Review
Criticism of Cholesterol Guidelines
— Cholesterol Is Not the Cause of Heart Attacks. Then What Is? —
See also ➡Supplementary Appendix~Click here~
MedCheck in English No.35
➡Download PDF Free ～Click here～
Editorial
Threat of a New Drug Disaster:What Can We Do?
Petition
Petition to Stop Plans for Routine Vaccination with Abrysvo ®
➡Rapid responses to BMJ article:
・Concerns Regarding Imbalance in Randomization in Pfizer’s RSV Vaccine Trial ~Click here~
・Concerns Regarding Primary Endpoint Assessment in Pfizer’s RSV Vaccine Trial ~Click here~No.1 No.2
・What does increased RSV-negative LRTI mean? ~Click here~
MedCheck in English No.34
➡Download PDF Free ～Click here～
Editorial
Questioning “No Serious Safety Concerns” in Vaccines
Review
Critical Analysis of the 2025 Hypertension Guidelines
MedCheck in English No.33
➡Download PDF Free ～Click here～
Editorial
Information Sharing to Prevent Adverse Reactions
Review
From Familiar Adverse Reactions to
Adverse Reaction-Prescribing Cascades
Adverse Reactions
Reproductive Toxicity of Paroxetine (Paxil)
-Focus on Withdrawal Syndrome and Persistent Pulmonary Hypertension-
Preclinical part of Summary Technical Documentation for paroxetine (Paxil)（in Japanese)
Memorial Tribute
Mr. Charles Medawar
A lifetime of activities breaking down barriers between patients and medical professionals
a
MedCheck in English No.32 Download PDF Free
Contents
Editorial
Why difficult to evaluate drug efficacy and harm?
New Products
RSV vaccine (Abrysvo®) :
Harms and suspected false negatives & allocation bias
Topic
How to Review Clinical Trials of new product
Intranazal flu vaccine, FluMist® as an example
Questions and Comments
What is the theoretical basis for healthy vaccinee effect?
a
Errata (Typos): PDF is already corrected
line 2-3, right column on p7
Before:vaccine group as in the placebo group (5 vs. 12 cases, respectively)
Corrected: placebo group as in the vaccine group (12 vs. 5 cases, respectively)
line 3 from the bottom of right column on p15
Before: 39.8% in the placebo group
Corrected:39.8% in the vaccine group
For others, see the table for Errata
